Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
CRISPR Therapeutics AG is a Swiss biotech company specializing in developing gene editing medicines using CRISPR/Cas9 technology. Its core focus includes therapies for genetic blood disorders like sickle cell disease and beta thalassemia, as well as oncology, autoimmune diseases, and cardiovascular conditions. The company leverages ex vivo and in vivo gene editing approaches, partnering with industry leaders to create potentially curative, transformative treatments.
This description was generated via AI from an annual report. Updated about 1 year ago.